Overview of Флюанксол

This section provides a clear overview of the identity, composition, and general purpose of Флюанксол (Flupentixol), strictly excluding information on specific dosages, side effects, and administration instructions.

Property	Description
Active Ingredient	Flupentixol / Flupentixol decanoate
Form	Film-coated tablets, Solution for injection (depot)
Pharmacological Class	Neuroleptic drug / First-generation antipsychotic
General Purpose	Management of psychotic disorders
Origin	Synthetic compound (Thioxanthene derivative)

What Type of Medicine is Флюанксол (Flupentixol)?

Флюанксол is a prescription-only medicine and a synthetic compound classified as a neuroleptic drug within the family of thioxanthene derivatives. It is categorized as a first-generation antipsychotic agent (FGA), a class that is clinically recognized for its effectiveness in managing chronic psychiatric conditions. This indicates that the medicine provides a verified benefit in maintaining stability and reducing the risk of relapse in severe thought disturbances.

The active ingredient is the INN Flupentixol. Its single-component product nature differentiates it from combination therapies, focusing its activity solely on the pathways targeted by the Flupentixol substance.

Composition and General Purpose

Flupentixol's function is to assist in the management of psychotic disorders by acting as a dopamine receptor antagonist in the brain, helping to regulate the activity of key chemical messengers.

The drug is supplied in two distinct dosage forms. The film-coated tablets are for daily oral use, while a highly distinguishing feature is the long-acting injectable form containing Flupentixol decanoate. This form is a specialized depot preparation suspended in a viscous oil solution, a composition that is specifically engineered for sustained release after a single intramuscular administration. This unique formulation is often preferred in clinical settings to support medication adherence, helping patients maintain consistent treatment without the variability of daily dosing. The overall therapeutic benefit is to help stabilize thought patterns and emotion by modulating nerve signals, defining its crucial role in achieving mental clarity and reducing inner distress.

What side effects are possible with Флюанксол?

Possible Side Effects and Safety Information

The safety profile of Flupentixol (Флюанксол) is defined by officially documented adverse reactions classified by frequency and body system, as established in regulatory prescribing information.

Frequency-Classified Adverse Reactions

The most frequently observed effects documented in regulatory labeling are classified as Very Common or Common.

Classification	Examples of Documented Effects
Very Common	Somnolence, Akathisia (restlessness), Dry mouth
Common	Insomnia, Dizziness, Headache, Tremor, Weight increase, Constipation, Vomiting, Tachycardia, Hypotension, Asthenia

These effects are generally grouped under the Nervous System and Gastrointestinal System disorders in official documents.

Serious and Contextual Safety Notes

The label documents specific reactions that, while rare, are considered clinically significant:

Serious Adverse Reactions: Rare events include Neuroleptic Malignant Syndrome (NMS), a potentially fatal condition, as well as blood disorders like Neutropenia, and cardiac events such as QT prolongation and Torsade de Pointes.
Duration Patterns: Certain effects, particularly extrapyramidal reactions, may be more prominent early in treatment or during dose escalation. Conversely, the risk of Tardive Dyskinesia is associated with long-term exposure.
Population-Specific: Specific safety notes apply to special populations, including caution for older adults and the contraindication in patients with severe hepatic impairment.
Restrictions: The use of Flupentixol is contraindicated in states involving circulatory collapse, coma, or a depressed level of consciousness.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes specific manifestations and severe outcomes associated with Flupentixol (Флюанксол) overdose, which necessitate immediate action. Suspected overdose is a severe event due to the risk of life-threatening complications, and professional medical intervention is required for management.

Documented Overdose Manifestations

System	Manifestations Listed in Regulatory Documents
Central Nervous System	Somnolence, sedation, confusion, progression to unconsciousness or coma.
Cardiovascular	Hypotension, sinus tachycardia, and severe cardiac arrhythmias, including QTc prolongation.
Neurological	Pronounced extrapyramidal symptoms and generalized convulsions or seizures.

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose. The regulatory profile defines the overdose as critical due to the potential for life-threatening events such as circulatory collapse, respiratory depression, and cardiac arrest. Because no specific antidote is known, management focuses entirely on providing monitored, symptomatic and supportive treatment.

Specific procedures described in official documents include ensuring the maintenance of respiration, carrying out continuous cardiac monitoring (ECG), and using activated charcoal or gastric lavage in appropriate circumstances. Neonates exposed in the third trimester are noted to be at risk for specific extrapyramidal and withdrawal symptoms.

Therapeutic Uses of Флюанксол

What Флюанксол Treats: Main Uses and Benefits

Флюанксол (Flupentixol) is commonly used for the long-term management of chronic psychotic illness and is also relevant in addressing symptoms of depression and anxiety. Its use plays a role in managing symptomatic fluctuations, supporting functional stability, and may assist with maintaining a consistent treatment approach. The medication is generally used across conditions presenting with chronic and episodic symptom patterns.

Core Therapeutic Focus

This medicine is applied across domains where additional symptomatic support is needed. Primary therapeutic uses involve addressing severe thought disturbances and perceptual issues like hallucinations and paranoid delusions, and helps address symptom clusters like diminished emotional engagement and social withdrawal. It is also considered relevant for easing associated depressive symptoms and generalized anxiety in specific contexts.

“The treatment approach supports patients during difficult episodes by easing distress and may help maintain functional stability in chronic conditions.”

Quick Fact: Relief for Sustained Stability

Quick Fact: Relief for Sustained Stability The long-acting preparation is generally applied in scenarios where adherence to a daily oral regimen is challenging, providing supportive relief that may help patients cope more steadily with symptom fluctuations.

Management Context

Флюанксол is used in clinical settings that involve recurrent or episodic manifestations. It is relevant when symptoms become temporarily overwhelming, supporting the patient by easing the overall symptom burden and helping to maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Флюанксол (Flupentixol)

The official eligibility profile for Flupentixol is strictly defined by regulatory documents, establishing absolute prohibitions and specific restrictions for various patient groups.

Populations For Whom Use is Contraindicated

Classification	Prohibited Populations
Absolute Contraindications	Patients with circulatory collapse, coma, or depressed level of consciousness due to any cause (e.g., intoxication) [Source 1.2, 1.5].
	Individuals with Phaeochromocytoma, blood dyscrasias, or known hypersensitivity to the drug or thioxanthene derivatives [Source 1.4, 1.6].

Populations Requiring Restriction or Conditional Use

Classification	Restricted Populations
Age-Related	Children and adolescents under 18 are not recommended to use this medicine; safety and efficacy are not established [Source 1.2]. Older adults require close supervision and may need reduced initial amounts [Source 1.5].
Physiological Status	Use is not recommended during pregnancy (especially the third trimester) and breastfeeding [Source 1.3].
Comorbidity-Based	Caution is mandatory in patients with severe hepatic impairment (reduced liver function), pre-existing cardiovascular disorders (like QT prolongation), epilepsy, or Parkinson’s disease [Source 1.1].

Regulatory authorities designate most adults who do not possess these contraindications as eligible for use, while mandating heightened caution for individuals with pre-existing conditions affecting the heart, liver, or central nervous system.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines documented interaction patterns for Flupentixol as reported in official government regulatory documents.

Contraindicated and Avoided Combinations

Co-administration with medicinal products known to significantly increase the QT interval is to be strictly avoided due to the exacerbated risk of malignant arrhythmias. This group includes certain Class Ia and III Antiarrhythmics, as well as other antipsychotics like thioridazine. Flupentixol is also formally contraindicated in states of depressed consciousness, including those caused by intoxication with alcohol or opiates.

Pharmacodynamic and Exposure Interactions

Flupentixol may enhance the sedative effect of CNS depressants, such as barbiturates and general anaesthetics. The drug may reduce the effect of levodopa and other adrenergic agents. Co-use with metoclopramide or piperazine is documented to increase the risk of extrapyramidal disorders.

Caution is advised when co-administering with drugs known to cause electrolyte disturbances (e.g., hypokalaemia, such as with certain diuretics), as this may increase the risk of cardiac rhythm disturbances. Patients with reduced hepatic function may experience decreased elimination, which can heighten the risk of clinically significant interactions.

Mechanism of Action

Pharmacodynamic Mechanism

Флюанксол (flupentixol) acts as an antagonist primarily at the dopamine D1 and D2 receptors within the central nervous system. This molecular interaction, a competitive binding at the receptor site, blocks the action of endogenous dopamine. The resulting D2 receptor antagonism leads to a direct modulation of postsynaptic dopaminergic neurotransmission in relevant brain regions.

Serotonergic Pathway Interaction

The molecule also exhibits affinity for 5-HT2 receptors. This affinity results in the competitive inhibition of 5-HT2 receptor-mediated signaling. The combined effect on both receptor families modifies the activity of key neuronal circuits. The compound is lipid-soluble, allowing it to rapidly cross the blood-brain barrier and achieve functional concentrations in the brain tissue, facilitating its mechanism of action on these major monoamine pathways.

Dosage and Administration Information

The medicine Флюанксол (Flupentixol) is used via two distinct official administration routes. The first is the oral form, which consists of film-coated tablets for daily dosing, generally taken once or twice daily and swallowed with water. Official labels state the tablets can be taken with or without food. For maintenance purposes, oral doses typically range up to 18 mg per day.

The second administration pathway is the long-acting injectable preparation, Flupentixol decanoate, which is administered exclusively by deep intramuscular injection into the gluteal region or lateral thigh, and is strictly not for intravenous use. This depot form is designated for long-term use and is not intended for therapy lasting less than three months.

The dosing schedule for the injectable form involves an initial test dose, typically 5 mg to 20 mg, to assess patient tolerability. Subsequent maintenance doses are usually given every 2 to 4 weeks, with typical maintenance doses ranging from 20 mg to 40 mg. Label instructions mandate that injection volumes exceeding 2 mL must be divided between two separate sites. Additionally, a critical procedural step involves aspiration before injection to ensure the oil-based solution does not inadvertently enter a blood vessel.

Official guidance specifies that dosage adjustments are necessary for older adults, who typically receive a starting dose reduced to a quarter or half the standard adult dose. Dose reductions are also advised for patients with reduced hepatic function, and the medicine is not recommended for children.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Флюанксол

The research landscape for Флюанксол primarily focuses on studies exploring management of severe thought disturbances and its evaluation as a potential long-term study approach. The evidence comes mainly from Randomized Controlled Trials (RCTs) and systematic reviews that research examined over several decades. These studies provide context on what has been observed so far in specific groups of patients.

Evidence for use in Chronic and Acute Psychotic Disorders

Research exploring the use of Флюанксол in conditions characterized by fluctuating or episodic manifestations utilized both oral tablets for short-term symptom measurement and the long-acting injectable (depot) form for long-term study. These studies monitored outcomes related to outcomes describing episodic or acute changes and outcomes reflecting daily functioning or activity level. RCTs typically compared Флюанксол to a placebo or to other established antipsychotic medications.

For the depot injection, studies primarily focused on long-term relapse rates—that is, how frequently patients experienced a recurrence of severe symptoms—and also monitored patient retention in the study. The evidence contributes to understanding symptom patterns in populations where daily dosing compliance was observed in some studies to be a factor.

RCTs and Long-term Study of Stability

Research examined how Флюанксол compared against other established medications and data show patterns related to changes in symptom scales. Comparative evidence against newer classes of medication is limited. Many of the foundational studies are older, and some comparisons among different depot preparations described similarities in outcomes, meaning comparative evidence is lacking to suggest a clear finding of difference over every other available option.

Evidence for use in Depressive Symptoms (Low Dose)

The research base exploring the low-dose oral formulation is separate from the primary study focus and was evaluated in conditions where symptoms may vary in intensity, such as neurotic depression and anxiety symptoms. Studies monitored outcomes related to mood improvement and anxiety reduction.

This evidence primarily consists of older, smaller double-blind trials and open-label studies. Findings were mixed and often relied on observing small-scale shifts in mood and anxiety rating scale scores over short assessment periods. Evidence is limited for this specific application, and the results can be difficult to interpret, especially in trials where Флюанксол was studied for use within a fixed-combination product alongside another medicine. This research provides context but not individual predictions for how an individual experiencing these conditions involving periods of heightened symptoms might respond.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guidelines: Psychosis and Schizophrenia in Adults

Frequently Asked Questions (FAQ)

Common questions about Флюанксол (FAQ)

Q: Are headaches a common side effect of Флюанксол?

According to official regulatory documents, headache is listed as a Common adverse effect of Флюанксол. This indicates that it is an effect observed in a noticeable percentage of patients in clinical trials.

Q: Is it common to feel drowsy when first starting Флюанксол?

Official product information states that drowsiness (somnolence) is a Very Common side effect. Information suggests that adverse effects are often more noticeable in the initial phase of treatment.

Q: Why does the packaging for Флюанксол have a warning about drowsiness?

Warnings are included because drowsiness is a Very Common effect of the medicine. Official guidance includes a warning regarding its potential impact on activities such as driving or operating machinery until the effect on the individual is known.

Q: Can Флюанксол affect blood pressure?

Yes, official regulatory documents indicate that Флюанксол can affect the circulatory system. Hypotension (low blood pressure) is listed as a Common side effect of the medicine.

Q: Does Флюанксол cause dry mouth?

Official regulatory documents list dry mouth as a Very Common adverse reaction of Флюанксол. This effect is frequently documented in patients taking the medicine.

Q: Does Флюанксол cause any dependence or addiction issues?

Флюанксол is officially classified as a neuroleptic or antipsychotic agent. This medication is not classified as a controlled substance that indicates a high dependence potential, but any concerns can be discussed further with a healthcare provider.

Q: Is Флюанксол approved for treating bipolar disorder?

The primary regulatory indication for Флюанксол is the management of psychotic disorders. Its regulatory approval does not specifically list bipolar disorder, though it belongs to a class of medication that is sometimes used in mood disorders.

Q: Can Флюанксол affect sleep patterns?

Yes, official regulatory documents list effects on sleep. Both drowsiness (somnolence) and insomnia (difficulty sleeping) are listed as documented adverse effects.

Q: Does Флюанксол treat anxiety?

Флюанксол is primarily approved for psychotic disorders. However, the molecule is described as having anxiolytic (anxiety-reducing) actions in regulatory-adjacent resources, and low-dose Флюанксол has been a subject of research for anxiety symptoms.

Q: How quickly does Флюанксол typically start to work?

Clinical data indicate that for the oral form, initial effects may become noticeable within the first few days after starting the medicine. The time required to achieve the full therapeutic benefit may vary for each individual.

Q: What is the typical starting time for feeling the full benefit of Флюанксол?

For the oral tablets, steady-state blood levels are usually reached after about seven days of consistent dosing. For the long-acting injectable, steady-state concentrations are reached after approximately three months of repeated administration.

Q: What is the average duration of a course of Флюанксол treatment?

The long-acting injectable (depot) preparation is not intended for therapy lasting less than three months. It is often used for long-term maintenance treatment to help support stability.

Q: Does Флюанксол cause weight gain?

Yes, official regulatory documents list Weight increase as a Common adverse reaction of Флюанксол. Weight changes are a documented effect that may be monitored during treatment.

Q: Is there a generic version of Флюанксол available?

The active ingredient in Флюанксол is Flupentixol, which is the generic name of the substance. Flupentixol is marketed under various trade names in the countries where it is approved.

Q: Is Флюанксол a type of tranquilizer?

Флюанксол is officially classified as a Neuroleptic drug and a First-generation antipsychotic. While it may have some mild sedative properties, its primary regulatory classification is antipsychotic.

Q: Why do some people feel more energized after starting Флюанксол?

Although drowsiness is a common effect, regulatory-adjacent literature notes that this medicine has historically been described as having Central Nervous System (CNS)-activating properties (energizing effects), which may occur in some individuals.

Q: Can you drive while taking Флюанксол?

Official guidance warns about the potential for drowsiness and dizziness. Patients are cautioned against driving or using complex machinery until they have established that the medicine does not impair their ability to perform these tasks.

Q: Does stopping Флюанксол suddenly cause withdrawal symptoms?

Official product information includes warnings about the possibility of acute withdrawal symptoms if the medicine is abruptly discontinued. These symptoms may include physical effects like nausea, sweating, or difficulty sleeping.

Q: Can Флюанксол be taken with supplements or herbal remedies?

Regulatory documents primarily detail interactions with other medicinal products that can cause sedative effects or electrolyte disturbances. It is advised to discuss the use of any supplements or herbal remedies with a healthcare provider.

Q: What is the half-life of Флюанксол?

Pharmacokinetic data available from regulatory-adjacent sources states the elimination half-life for the oral form is approximately 35 hours.

Q: Can Флюанксол cause changes in mood or personality?

Official safety documents list mood changes and depression as documented psychiatric adverse effects.

Q: How is the effect of Флюанксол monitored during treatment?

Official regulatory documents state that regular monitoring is required, including checking the ECG (due to the risk of QT prolongation) and monitoring for blood disorders.

Q: Why is Флюанксол sometimes used in low doses?

Research literature specifically notes that low doses of Флюанксол have been investigated for their antidepressant and anti-anxiety effects in certain populations.

Q: Is it true that Флюанксол is used more in certain countries than others?

Regulatory sources confirm Флюанксол is approved and marketed in many countries worldwide, including in Europe, Canada, and Australia.

How should Флюанксол be stored and disposed of?

How to Store and Dispose of Флюанксол (Fluanxol)

Storage and disposal requirements for Fluanxol are set by regulatory authorities to ensure product stability and safety. The medicine must be stored in its original container and kept out of the sight and reach of children.

Required Storage Conditions

Condition	Regulatory Requirement
Temperature	Store below 25 C (Room temperature) and protect from heat.
Prohibitions	Do not refrigerate and do not allow to freeze.
Protection	Keep in the outer carton to protect from light and moisture.
Stability	Do not use after the expiry date printed on the packaging.

Disposal Instructions

Unused or expired Флюанксол must be disposed of safely and in accordance with local regulatory requirements. The medicine should not be disposed of in household waste or wastewater. The required procedure is to return any unused medicinal product to a pharmacist or an approved collection scheme for proper handling.

Флюанксол